Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.

The Annals of pharmacotherapy - 1 Mar 2007

Mulder Hans, Heerdink Eibert R, van Iersel Elsje E, Wilmink Frederik W, Egberts Antoine C G

Abstract excerpt

BACKGROUND: Despite a large number of studies investigating the potential clinical relevance of CYP2D6 genotyping in preventing treatment failure (eg, insufficient efficacy and/or unacceptable adverse effects), the prevalence of patients using drugs metabolized by that isoenzyme is relatively unknown. OBJECTIVE: To investigate the prevalence of patients in different populations using drugs metabolized by CYP2D6....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antidepressive Agents

Share to Antipsychotic Agents

Share to Cytochrome P-450 CYP2D6

Share to Depression

Share to Mental Disorders

Share to Pharmacogenetics

Source

Identifiers

PMID: 17341534
DOI: 10.1345/aph.1H482

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.PMID 17341534Read ↗

The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.Semantic proximity Read ↗

Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study.Semantic proximity Read ↗

Availability of CYP2D6 genotyping results in general practitioner and community pharmacy medical records.Semantic proximity Read ↗

The potential of CYP2D6 phenotyping to improve opioid dosing strategiesSemantic proximity Read ↗

Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?Semantic proximity Read ↗

Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapySemantic proximity Read ↗

Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.Semantic proximity Read ↗

The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry.Semantic proximity Read ↗

Association between CYP2D6 genotype and treatment effectiveness and safety in 99 hospitalized patients with major depressive disorder - a retrospective cohort studySemantic proximity Read ↗

Screening for genotypic and phenotypic variations in CYP450 activity in patients with therapeutic problems in a psychiatric setting, a retrospective study.Semantic proximity Read ↗

Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.Semantic proximity Read ↗

CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.